ライフサイエンスコーパス: MERS-CoV

1 MERS-CoV can infect multiple host species and cause seve

2 MERS-CoV causes a severe respiratory disease with high f

3 MERS-CoV continues to be an endemic, low-level public he

4 MERS-CoV has a zoonotic origin and poses a major threat

5 MERS-CoV infection during pregnancy may be associated wi

6 MERS-CoV is believed to have emerged from bats and passe

7 MERS-CoV is deadly, but this work shows that its clinica

8 MERS-CoV is still circulating in the human population, a

9 MERS-CoV replicated transiently in the respiratory and,

10 MERS-CoV was first identified in June 2012 and has since

11 MERS-CoV-infected lungs revealed mononuclear cell infilt

12 During the study period, 216 MERS-CoV cases were reported.

13 ich is in direct contact with host cells; 4) MERS-CoV frequently transmitted back and forth between h

14 e of AgNPs, giving detection limits of 1.53 (MERS-CoV), 1.27 (MTB), and 1.03 nM (HPV).

15 the transmission patterns underlying the 681 MERS-CoV cases detected in the Kingdom of Saudi Arabia (

16 tistical model to a line list describing 721 MERS-CoV infections detected between June 7, 2012, and J

17 (95% confidence interval (CI): 1,327, 1,883) MERS-CoV infections occurred in this interval, which is

18 eceptor binding domain protein vaccine and a MERS-CoV fusion inhibitor, we demonstrated the value of

19 ERS-CoV neutralizing antibody treatment or a MERS-CoV spike protein vaccine protected the engineered

20 ical screening of vaccines and drugs against MERS-CoV infection and disease.

21 accine protected the engineered mice against MERS-CoV-induced ARDS.

22 There are no treatment options against MERS-CoV for humans or animals, and there are no large-s

23 f rhesus macaques confers protection against MERS-CoV-induced radiographic pneumonia, as assessed usi

24 otein induce potent immune responses against MERS-CoV and RABV.

25 -scale clinical trials for therapies against MERS-CoV.

26 it high neutralizing antibody titers against MERS-CoV.

27 Although MERS-CoV generally causes subclinical or mild disease, i

28 tive risks of death and severe disease among MERS-CoV patients in the Middle East between 2012 and 20

29 in the distribution of DPP4 expression among MERS-CoV susceptible species, which might influence vari

30 The outbreaks of SARS-CoV and MERS-CoV and the continuing diagnosis of new MERS cases

31 Both SARS-CoV and MERS-CoV are zoonotic infections, with bats as the prima

32 imatinib, as inhibitors of both SARS-CoV and MERS-CoV in vitro Here we show that the anti-CoV activit

33 Treatment of SARS-CoV and MERS-CoV infection is limited to providing supportive th

34 r a conserved epitope shared by SARS-CoV and MERS-CoV is a potential strategy for developing pan-coro

35 The emergence of SARS-CoV and MERS-CoV provides evidence that coronaviruses are curren

36 bl2), as required for efficient SARS-CoV and MERS-CoV replication in vitro These data demonstrate tha

37 uman CoVs (including the deadly SARS-CoV and MERS-CoV) and their related zoonotic CoVs, our structure

38 o zoonotic coronaviruses (CoVs)-SARS-CoV and MERS-CoV-have crossed species to cause severe human resp

39 epitope was also recognized in SARS-CoV- and MERS-CoV-infected human leukocyte antigen DR2 and DR3 tr

40 mples were screened by recombinant ELISA and MERS-CoV seropositivity was confirmed by recombinant imm

41 coronavirus, mouse hepatitis virus (MHV) and MERS-CoV, encode 2',5'-phosphodiesterases (2',5'-PDEs) t

42 ) dipeptidyl peptidase 4 (DPP4) receptor and MERS-CoV replicated efficiently in Jamaican fruit bat ce

43 the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those i

44 rotein convertases in MERS-S-transfected and MERS-CoV-infected cells and that several RXXR motifs loc

45 Anti-MERS-CoV antibodies were confirmed in 15 (0.15%; 95% CI

46 hat m336, an exceptionally potent human anti-MERS-CoV antibody, is almost germline with only one soma

47 Double staining immunoassays that used anti-MERS-CoV antibodies paired with immunohistochemistry for

48 for highly pathogenic coronaviruses, even as MERS-CoV is spreading throughout the Middle East.

49 However, in vivo studies are limited because MERS-CoV cannot infect wild-type mice due to incompatibi

50 e East respiratory syndrome betacoronavirus (MERS-CoV) and found that 11 of the 22 residues in the pF

51 ation of mouse DPP4 plays a role in blocking MERS-CoV infection.

52 ke and subsequent infection of human pDCs by MERS-CoV.

53 udy presents evidence for a strategy used by MERS-CoV nsp1 to inhibit host gene expression that has n

54 in the RBD of representative human and camel MERS-CoV strains during the 2012-2015 outbreaks.

55 S proteins of representative human and camel MERS-CoV strains identified during the 2012-2015 outbrea

56 ion by divergent circulating human and camel MERS-CoV strains.

57 vaccines against circulating human and camel MERS-CoV strains.

58 ein with multiple changes derived from camel MERS-CoV strains.

59 likely to influence the success of candidate MERS-CoV vaccines.

60 highly effective subunit vaccines to combat MERS-CoV and other life-threatening viruses.

61 ountermeasures (MCM) are available to combat MERS-CoV infections.

62 ntly, therapeutic countermeasures comprising MERS-CoV neutralizing antibody treatment or a MERS-CoV s

63 These mutations severely compromised MERS-CoV infection into human lung-derived cells, but ha

64 identified all cases of laboratory-confirmed MERS-CoV infection in Jeddah that were reported to the S

65 Of 255 patients with laboratory-confirmed MERS-CoV infection, 93 died (case fatality rate, 36.5%).

66 alization escape viruses and by constructing MERS-CoV S variants for serological assays.

67 ll shape the capacity to prevent and control MERS-CoV or new emerging disease transmission.

68 then analyzed the ability of mice to control MERS-CoV infection.

69 respiratory syndrome-associated coronavirus (MERS-CoV) cause high case fatality rates and remain majo

70 respiratory syndrome-associated coronavirus (MERS-CoV).

71 ceptor-binding domain from MERS coronavirus (MERS-CoV).

72 ory syndrome and was named MERS coronavirus (MERS-CoV).

73 iddle East Respiratory Syndrome coronavirus (MERS-CoV) and development of a humanized mouse model for

74 iddle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome CoV (SAR

75 iddle East respiratory syndrome coronavirus (MERS-CoV) as a cause of severe respiratory disease highl

76 iddle East respiratory syndrome coronavirus (MERS-CoV) belongs to beta group of coronavirus and was f

77 iddle East respiratory syndrome coronavirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidas

78 iddle East respiratory syndrome coronavirus (MERS-CoV) cause significant morbidity and morality.

79 iddle East respiratory syndrome coronavirus (MERS-CoV) causes life-threatening disease.

80 iddle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory illness in humans.

81 iddle East respiratory syndrome coronavirus (MERS-CoV) develop severe symptoms, which likely leads to

82 iddle East respiratory syndrome coronavirus (MERS-CoV) during pregnancy.

83 iddle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic res

84 iddle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 as the causative agent of a se

85 iddle East respiratory syndrome coronavirus (MERS-CoV) encode multifunctional papain-like proteases (

86 iddle East respiratory syndrome coronavirus (MERS-CoV) encodes the conserved macro domain within non-

87 iddle East respiratory syndrome coronavirus (MERS-CoV) has been attributed to overcrowding, delayed d

88 iddle East respiratory syndrome coronavirus (MERS-CoV) has been shown to infect both humans and drome

89 iddle East Respiratory Syndrome coronavirus (MERS-CoV) has repeatedly caused outbreaks in the Arabian

90 iddle East respiratory syndrome coronavirus (MERS-CoV) highlights the zoonotic potential of Betacoron

91 iddle East respiratory syndrome coronavirus (MERS-CoV) infection causes an acute respiratory illness

92 iddle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported worldwide, with 6

93 iddle East respiratory syndrome coronavirus (MERS-CoV) infection is associated with a high case-fatal

94 iddle East respiratory syndrome coronavirus (MERS-CoV) infection occurred in Jeddah, Saudi Arabia, in

95 iddle East respiratory syndrome coronavirus (MERS-CoV) infections are still unknown.

96 iddle East respiratory syndrome coronavirus (MERS-CoV) infections occurred across Saudi Arabia with a

97 iddle East respiratory syndrome coronavirus (MERS-CoV) infects humans from zoonotic sources and cause

98 iddle East respiratory syndrome coronavirus (MERS-CoV) into human populations demonstrates the zoonot

99 iddle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human CoV that emerged

100 iddle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic respiratory virus that

101 iddle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic respiratory virus that

102 iddle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its

103 iddle East respiratory syndrome coronavirus (MERS-CoV) is a novel virus that emerged in 2012, causing

104 iddle East respiratory syndrome coronavirus (MERS-CoV) is an emerging human pathogen that is the caus

105 iddle East respiratory syndrome coronavirus (MERS-CoV) is an emerging pathogen, first recognized in 2

106 iddle East respiratory syndrome coronavirus (MERS-CoV) is an important emerging pathogen that was fir

107 iddle East respiratory syndrome coronavirus (MERS-CoV) outbreak represents another prime example of v

108 iddle East respiratory syndrome coronavirus (MERS-CoV) remains a significant threat for public health

109 iddle East respiratory syndrome coronavirus (MERS-CoV) targets the epithelial cells of the respirator

110 iddle East respiratory syndrome coronavirus (MERS-CoV) transmitted from bats to humans, we compared t

111 iddle East respiratory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an e

112 iddle East respiratory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an e

113 iddle East respiratory syndrome coronavirus (MERS-CoV) was first identified in a human with severe pn

114 iddle East respiratory syndrome coronavirus (MERS-CoV), and human CoV 229E (HCoV-229E).

115 iddle East respiratory syndrome coronavirus (MERS-CoV), encode a papain-like protease (PLpro) that po

116 iddle East respiratory syndrome coronavirus (MERS-CoV), including travel-associated cases, continue t

117 iddle East respiratory syndrome coronavirus (MERS-CoV), Mycobacterium tuberculosis (MTB), and human p

118 le Eastern respiratory syndrome coronavirus (MERS-CoV).

119 iddle East respiratory syndrome coronavirus (MERS-CoV).

120 iddle East respiratory syndrome coronavirus (MERS-CoV).

121 iddle East respiratory syndrome-coronavirus (MERS-CoV) infections.

122 % fatalities and now spread to 27 countries, MERS-CoV poses a significant ongoing threat to global hu

123 V) and Middle East respiratory syndrome CoV (MERS-CoV).

124 imilarly to SUD, the PL(pro)s from SARS-CoV, MERS-CoV, and HCoV-NL63 physically interact with and sta

125 erefore, the activity of PLPs from SARS-CoV, MERS-CoV, and mouse hepatitis virus was evaluated agains

126 f the FPs of S glycoproteins of 3 beta-CoVs, MERS-CoV, SARS-CoV, and MHV, and demonstrated that they

127 Currently, MERS-CoV is still spreading, as new infections continue

128 uch as camels, as well as humans from deadly MERS-CoV and RABV infections.

129 Since RBD mutations occur in different MERS-CoV isolates and antibody escape mutants, cross-neu

130 e mutants, cross-neutralization of divergent MERS-CoV strains by RBD-induced antibodies remains unkno

131 We now demonstrate that in addition to DPP4, MERS-CoV binds to sialic acid (Sia).

132 events might have happened frequently during MERS-CoV's evolutionary history and the positive selecti

133 degree of immune activation observed during MERS-CoV infection.

134 MERS-CoV strains, as well as antibody escape MERS-CoV mutants.

135 during the 2012-2015 outbreaks, 5 MAb escape MERS-CoV mutants, and 2 live human MERS-CoV strains.

136 cts and depletion of macrophages exacerbates MERS-CoV-induced pathology and clinical symptoms of dise

137 No evidence of extrapulmonary MERS-CoV antigens were detected, including the kidney.

138 owever, the pathogenesis of severe and fatal MERS-CoV infection is unknown.

139 ng this strategy as a promising approach for MERS-CoV vaccine development.

140 d routinely collected epidemiologic data for MERS-CoV cases reported in Saudi Arabia during 1 January

141 for better understanding of risk factors for MERS-CoV transmission.

142 Dromedary camels, hosts for MERS-CoV, are implicated in direct or indirect transmiss

143 iction at the receptor or cellular level for MERS-CoV.

144 n mAb, have been chosen as promising MCM for MERS-CoV.

145 d development of a humanized mouse model for MERS-CoV infection, which was used to demonstrate the th

146 World Health Organization questionnaire for MERS-CoV case-control studies to assess risk factors for

147 While the cell surface receptor for MERS-CoV has been identified as dipeptidyl peptidase 4 (

148 r ability to act as functional receptors for MERS-CoV.

149 d cells and whether cleavage is required for MERS-CoV infectivity.

150 he role of bats as a potential reservoir for MERS-CoV.

151 pothesis of bats as ancestral reservoirs for MERS-CoV.

152 HCoV-229E evolution provides a scenario for MERS-CoV emergence.

153 lder than 15 years might be seropositive for MERS-CoV in Saudi Arabia.

154 nal antibodies as potential therapeutics for MERS-CoV infection.

155 in Jeddah and Riyadh were not different from MERS-CoV EMC/2012 in replication, escape of interferon r

156 Comparison of macro domains from MERS-CoV and other human CoVs revealed structural differ

157 ental vaccine vector BNSP333, and the RABV G-MERS-CoV S1 fusion protein was efficiently expressed and

158 As part of its viral genome, MERS-CoV encodes a papain-like protease (PLpro) that has

159 on prevention and control measures for human MERS-CoV infections.

160 rol studies to assess risk factors for human MERS-CoV seropositivity at a farm complex in Qatar.

161 Ab escape MERS-CoV mutants, and 2 live human MERS-CoV strains.

162 e mutations detected in representative human MERS-CoV strains from the 2012, 2013, 2014, and 2015 out

163 DPP4 species-specific differences impacting MERS-CoV host range and better inform our understanding

164 DPP4 species-specific differences impacting MERS-CoV host range and may inform MERS-CoV mouse model

165 aling species-specific differences impacting MERS-CoV host range.

166 emergence and host susceptibility.IMPORTANCE MERS-CoV is a recently emerged zoonotic virus that is st

167 These mutations are present in MERS-CoV spike, explaining why MERS-CoV infects human ce

168 e wide range of disease severity reported in MERS-CoV-infected humans, which will aid in investigatin

169 history and the positive selection sites in MERS-CoV's S protein might enable it to infect human.

170 preexisting pulmonary disease could increase MERS-CoV receptor abundance and predispose individuals t

171 impacting MERS-CoV host range and may inform MERS-CoV mouse model development.

172 Efforts to inhibit MERS-CoV infection by targeting host cell proteases shou

173 ace Sia by neuraminidase treatment inhibited MERS-CoV entry of Calu-3 human airway cells, thus provid

174 cted humans, which will aid in investigating MERS-CoV disease pathogenesis.

175 The majority of patients in the Jeddah MERS-CoV outbreak had contact with a health care facilit

176 only low-level incorporation of full-length MERS-CoV S into RABV particles.

177 cy in protecting transgenic mice from lethal MERS-CoV challenge.

178 ce treated with m336 prior to or post lethal MERS-CoV challenging were fully protected, compared to c

179 infection by divergent pseudotyped and live MERS-CoV strains, as well as antibody escape MERS-CoV mu

180 nge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challeng

181 e discuss biochemical determinants mediating MERS-CoV host cell permissivity, including virus spike i

182 e viral receptor, DPP4, and did not modulate MERS-CoV infectivity.

183 subunit to gain access to translating mRNAs, MERS-CoV nsp1 was distributed in both the nucleus and th

184 S-CoV nsp1, the mRNA degradation activity of MERS-CoV nsp1, most probably triggered by its ability to

185 ality rate prompted us to analyze aspects of MERS-CoV pathogenesis, especially its interaction with i

186 high-specificity, low-affinity attachment of MERS-CoV to sialoglycans during the preattachment or ear

187 ns designated S1(A) through S1(D) Binding of MERS-CoV to the cell surface entry receptor dipeptidyl p

188 nsmission have contributed to the buildup of MERS-CoV epidemics in KSA.

189 e first autopsy performed on a fatal case of MERS-CoV in the world, which was related to a hospital o

190 facility, a person with a confirmed case of MERS-CoV infection, or someone with severe respiratory i

191 In Saudi Arabia, 5 cases of MERS-CoV infection among pregnant women were reviewed, a

192 therefore may be significant determinants of MERS-CoV virulence.

193 When given a high dose of MERS-CoV, our transgenic mice expressing hCD26/DPP4 vira

194 and between humans means that the drivers of MERS-CoV epidemics remain poorly characterized.

195 analyses to study the evolution dynamics of MERS-CoV among different host species with genomic data.

196 their escape from the inhibitory effects of MERS-CoV nsp1.

197 Cases occurring later in the emergence of MERS-CoV and among health-care workers were less serious

198 coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusi

199 Although the overall impact of MERS-CoV PLpro function is observed to be essential, dif

200 Peptidomimetic inhibitors of MERS-CoV 3CL(pro) were synthesized and utilized in analy

201 This study elucidates the interaction of MERS-CoV with APCs and pDCs, particularly the induction

202 As a result, the interface of MERS-CoV and human interferon-stimulated gene product 15

203 m MERS-immune camels augment the kinetics of MERS-CoV clearance and reduce the severity of pathologic

204 by determining both the ID50 and the LD50 of MERS-CoV in order to establish both an infection model a

205 with a potential working dose of 10 LD50 of MERS-CoV were subsequently evaluated.

206 e fully immune to challenge with 100 LD50 of MERS-CoV.

207 rhesus macaque and common marmoset model of MERS-CoV disease were analyzed.

208 acterized a lethal transgenic mouse model of MERS-CoV infection and disease that globally expresses h

209 Therefore, development of mouse models of MERS-CoV has been hampered by the fact that MERS-CoV doe

210 These new mouse models of MERS-CoV should be useful for investigation of early dis

211 rhesus macaque and common marmoset models of MERS-CoV span the wide range of disease severity reporte

212 Models of MERS-CoV-induced severe respiratory disease have been di

213 To estimate the number of MERS-CoV infections that have occurred in the Kingdom of

214 Investigations into the origin of MERS-CoV have focused on two potential reservoirs: bats

215 l strategy wherein the cytoplasmic origin of MERS-CoV mRNAs facilitates their escape from the inhibit

216 The ongoing outbreak of MERS-CoV has resulted in 1,791 cases of MERS and 640 dea

217 As outcomes of MERS-CoV infection in patients differ greatly, ranging f

218 uces a new tool to probe the pathogenesis of MERS-CoV and related viruses through the removal of vira

219 e critical insights into the pathogenesis of MERS-CoV in humans.

220 The spike protein of MERS-CoV (MERS-S) facilitates viral entry into host cell

221 combinant types; 2) The spike (S) protein of MERS-CoV was under strong positive selection when MERS-C

222 related activities may pose a higher risk of MERS-CoV infection, as may cross-border movements of cam

223 th the general population, seroprevalence of MERS-CoV antibodies was significantly increased by 15 ti

224 2,3-linked Sias and the predominant sites of MERS-CoV replication in the upper and lower respiratory

225 ans, we compared the virus surface spikes of MERS-CoV and a related bat coronavirus, HKU4.

226 The first structure of MERS-CoV PLpro in complex with this domain exposed the i

227 Subsequently, the structure of MERS-CoV PLpro was solved to 2.4 A in complex with the C

228 lable vaccines or therapeutics, the study of MERS-CoV pathogenesis is crucial for its control and pre

229 lial syncytial cells as important targets of MERS-CoV antigen; double immunostaining with dipeptidyl

230 In tests of MERS-CoV-infected dromedaries, we found viruses related

231 two pFPs differed significantly from that of MERS-CoV and each other, most of the pFP mutants of SARS

232 , with efficacy proportional to the titer of MERS-CoV-neutralizing serum antibody.

233 Furthermore, active transcription of MERS-CoV N RNA and subsequent N protein expression were

234 ation of a vaccine and drug for treatment of MERS-CoV infection.

235 ansmission occurring during the treatment of MERS-CoV infections imported to Thailand.

236 ERS fatalities has hindered understanding of MERS-CoV pathogenesis.

237 rom MERS cases has hindered understanding of MERS-CoV pathogenesis.

238 actors contributing to the high virulence of MERS-CoV.

239 (+) T cells, or macrophages has no effect on MERS-CoV replication in the lungs of infected mice.

240 Relative to the parental MERS-CoV, MERSMA viruses contained 13-22 mutations, incl

241 pectrum RBD-based subunit vaccine to prevent MERS-CoV infection.

242 tract tissues of humans and camels reflects MERS-CoV tropism.

243 for the inflammatory response in regulating MERS-CoV pathogenesis in vivo IMPORTANCE: The Middle Eas

244 for the inflammatory response in regulating MERS-CoV pathogenesis in vivo The Middle East respirator

245 Serial MERS-CoV passage in these engineered mice was then used

246 serum-neutralizing activity against several MERS-CoV strains in mice and non-human primates.

247 While bat, camel, and human DPP4 support MERS-CoV infection, several DPP4 orthologs, including mo

248 address some of the uncertainty surrounding MERS-CoV epidemiology.

249 onses and immunity of the mice that survived MERS-CoV infection.

250 th recommendations regarding when to suspect MERS-CoV, how to make a diagnosis, and what infection co

251 The synthetic MERS-CoV pFP core peptide (955IAGVGWTAGL964) induced ext

252 trifugation experiments and demonstrate that MERS-CoV 3CL(pro) undergoes significant ligand-induced d

253 Therefore, this study demonstrates that MERS-CoV RBD is an important vaccine target able to indu

254 MERS-CoV has been hampered by the fact that MERS-CoV does not replicate in commonly available mouse

255 Our results indicate that MERS-CoV maintains the ability to replicate in bats with

256 n at the translational level, we report that MERS-CoV nsp1 also exhibits a conserved function to nega

257 Here, biophysical techniques revealed that MERS-CoV PLpro chiefly engages human ISG15 through its C

258 cal ultracentrifugation studies support that MERS-CoV 3CL(pro) is a weakly associated dimer (Kd appro

259 The MERS-CoV is an emerging virus, which already infected mo

260 The MERS-CoV outbreak began in Saudi Arabia and has spread t

261 titration calorimetry, we characterized the MERS-CoV macro domain as a more efficient adenosine diph

262 eloped a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to th

263 ivated rabies virus particles containing the MERS-CoV S1 protein induce potent immune responses again

264 ivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface.

265 icted to infection at the level of DPP4, the MERS-CoV receptor, we generated mice with humanized exon

266 accinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lo

267 al bases to further evaluate the role of the MERS-CoV macro domain in the host response via ADP-ribos

268 and may explain the efficient binding of the MERS-CoV macro domain to ADP-ribose.

269 Furthermore, the crystal structure of the MERS-CoV macro domain was determined at 1.43-A resolutio

270 Pulmonary expression of the MERS-CoV receptor, dipeptidyl peptidase 4, was similar i

271 that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminu

272 In vitro, the MERS-CoV spike glycoprotein interacted with Jamaican fru

273 including virus spike interactions with the MERS-CoV cell surface receptor dipeptidyl peptidase 4 (D

274 he structure of Fab m336 in complex with the MERS-CoV receptor-binding domain reveals that its IGHV1-

275 glycosylation site that acts as a barrier to MERS-CoV infection.

276 The ongoing exposure of humans to MERS-CoV from the reservoir is of major concern, given t

277 lso suggest minimal pre-existing immunity to MERS-CoV in humans.

278 a-pig and ferret) are naturally resistant to MERS-CoV.

279 replication and the local immune response to MERS-CoV infection likely play a role in pulmonary patho

280 mouse model to analyze the host response to MERS-CoV infection using immunological assays and transc

281 By understanding the immune response to MERS-CoV we can develop targeted therapies to inhibit pa

282 nsgenic mice shown to be highly sensitive to MERS-CoV infection and disease.

283 idase 4 receptor, making mice susceptible to MERS-CoV infection and replication.

284 d high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directe

285 BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly red

286 ay with human erythrocytes and intact virus, MERS-CoV Sia-binding activity was assigned to S subdomai

287 CoV was under strong positive selection when MERS-CoV transmitted from their natural host to human; 3

288 for use in animals and humans in areas where MERS-CoV is endemic.

289 re present in MERS-CoV spike, explaining why MERS-CoV infects human cells.

290 p, we inoculated 10 Jamaican fruit bats with MERS-CoV.

291 22% (95% CI: 18, 25) of those infected with MERS-CoV died.

292 l studies indicate that humans infected with MERS-CoV exhibit pathology consistent with the late stag

293 pulmonary manifestations when infected with MERS-CoV would advance the field.

294 s in the Middle East have been infected with MERS-CoV, and some contain high titers of antibody to th

295 lly or therapeutically to mice infected with MERS-CoV, indicating that this may be a useful intervent

296 moter that are susceptible to infection with MERS-CoV.

297 Upon inoculation with MERS-CoV, human DPP4 knockin (KI) mice supported virus r

298 d both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipe

299 Nine camel workers with MERS-CoV antibodies and 43 workers without antibodies we

300 derstanding viral deISGylase activity within MERS-CoV and other CoVs.IMPORTANCE Coronaviruses, such a